Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

Filter
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:

*Includes seizure clusters and acute or prolonged seizures

137 result(s)

phase 3

FINTEPLA® (fenfluramine)

Lennox-Gastaut Syndrome
View

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study

Kelly G Knupp, Ingrid E Scheffer, Berten Ceulemans et al.  November 09, 2022
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis.

Armstrong April, K. Fahrbach, Leonardi Craig et al.  July 07, 2022
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled results from phase 2 and phase 3 randomized clinical trials.

Gordon B. Kenneth, Langley G. Richard, Warren B. Richard et al.  July 01, 2022
phase 3

FINTEPLA® (fenfluramine)

Lennox-Gastaut Syndrome
View

Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial

Kelly G Knupp, Ingrid E Scheffer, Berten Ceulemans et al.  May 02, 2022
phase 2

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: an open-label trial 

Mark Kristof Farkas, Harriet Kang, András Fogarasi et al.  February 23, 2022
phase 4

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17

Armstrong W. April, Blauvelt Andrew, Mrowietz Ulrich et al.  February 15, 2022
phase 4

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab self-injection devices: Two multicenter, randomized, open-label studies on self-administration by patients with psoriasis.

Bagel Jerry, Machala Magdalena, Hellot Scarlett et al.  January 31, 2022
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.

Frick Andrew, J.G. Krueger, Glatt Sophie et al.  December 27, 2021
phase 3

FINTEPLA® (fenfluramine)

Dravet Syndrome
View

Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome

J Helen Cross, Bradley S Galer, Antonio Gil-Nagel et al.  November 02, 2021
phase 3

FINTEPLA® (fenfluramine)

Dravet Syndrome
View

Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany

Adam Strzelczyk, Milka Pringsheim, Thomas Mayer et al.  August 10, 2021